Loading
Latest filing published 23 Sept 2026 for Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation), €79k.
No signal scores available.
Gilad Aharon appears in our data through filings on Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) shares, published by SEDI. The record holds 5 filings, for trades running from 15 June 2026 to 22 September 2026.
No open-market sale appears; the market trades are 1 purchase worth €79k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 1 option exercise.
On 23 September 2026 came the latest disclosure, an open-market purchase for €79k in Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation). This summary is built from SEDI disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations